- Home
- BIOA
as 05-08-2025 4:00pm EST
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 144.1M | IPO Year: | 2024 |
| Target Price: | $5.67 | AVG Volume (30 days): | 246.5K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.88 - $26.62 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,451,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioAge Labs Inc. Common Stock News
BIOA Breaking Stock News: Dive into BIOA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
Simply Wall St.
3 days ago
With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest
Insider Monkey
18 days ago
BioAge Labs, Inc. (BIOA): A Bull Case Theory
Simply Wall St.
a month ago
Several Insiders Invested In BioAge Labs Flagging Positive News
GlobeNewswire
2 months ago
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
PR Newswire
2 months ago
BioArctic receives Orphan Drug Designation for exidavnemab the US
GlobeNewswire
3 months ago
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
BioPharma Dive
3 months ago
BioAge drops obesity drug; Akero, 89bio cash in on MASH data
Compare BIOA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIOA BioAge Labs Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.